David Cory, Eiger BioPharmaceuticals CEO (Eiger via MultiVu)
March 17, 2022 10:12 AM EDTUpdated 01:05 PM
R&D
Coronavirus

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

John Carroll

Editor & Founder

The big hey­day of mar­ket delir­i­um re­lat­ed to any­thing pos­i­tive in new Covid-re­lat­ed da­ta has pe­tered out as Omi­cron pass­es over, but lit­tle Eiger Bio­Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times